OTLC - Oncotelic Therapeutics posts positive topline results from COVID-19 trial

Oncotelic Therapeutics ([[OTLC]] -4.6%) posts positive topline data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal against COVID-19 in India.PulmoHeal, which is being developed by Oncotelic in partnership with Windlas Biotech Private, when added to the standard of care ((SOC)), accelerated the recovery of patients with mild to moderate COVID-19, across all COVID-19 symptoms examined.Oxygen saturation fully recovered by day-28 with PulmoHeal + SOC ((p=0.0003)), but not with SOC alone ((p=ns)). SOC included remdesivir, dexamethasone, heparin, ivermectin and others."Here we are seeing a full recovery of normal lung functions (O2 saturation and respiratory rate) when treated with PulmoHeal," said Saran Saund, CBO and GM of AI Division, Oncotelic.

For further details see:

Oncotelic Therapeutics posts positive topline results from COVID-19 trial